Table 5.
Characteristics, positive surgical rates, and biochemical recurrence in comparative studies evaluating LRP and RARP.
| Author, years country (ref) |
Asimakopoulos, 201116) |
Asimakopoulos, 201318) |
Hakimi, 200919) |
Papachristos, 201520) |
Park, 201321) |
Ploussard, 201422) |
Porpiglia, 201317) |
Stolzenburg, 201323) |
Wolanski, 201324) |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study design |
RCT |
Prospective |
Retrospective |
Retrospective |
Retrospective |
Prospective |
RCT |
Prospective |
Retrospective |
|||||||||
| Procedure | LRP | RARP | LRP | RARP | LRP | RARP | LRP | RARP | LRP | RARP | LRP | RARP | LRP | RARP | LRP | RARP | LRP | RARP |
| No. of cases | 60 | 52 | 91 | 136 | 75 | 75 | 100 | 100 | 144 | 183 | 1377 | 1009 | 60 | 60 | 100 | 100 | 87 | 73 |
| Age, years medians/means | 61.1 ± 5.1 | 59.6 ± 5.4 | 63 ± 4.9 | 60 ± 5.5 | 59.6 (43-72) | 59.8 (42-71) | 62.5 (45-72) | 60.5 (45-75) | 67 (38-77) | 67 (44-71) | 62.7 | 62.7 | 64.7 ± 5.9 | 63.9 ± 6.7 | 61.33 ± 7.4 | 61.21 ± 7.7 | 61.3 ± 6.5 | 61.4 ± 7.2 |
| PSA, ng/ml, median/means | 7.37 (1.5-9.15) | 8.9 (5.8-92) | 6 | 6.4 | 7.5 | 8.4 | 7.1 (1.8-37) | 5.5 (0.72-35) | 5.84 (0.008-41.26) | 4.98 (0.05-51.46) | 9.8 | 9.2 | 8.3 ± 6.5 | 6.9 ± 4.2 | 10.7 ± 11.49 | 8.75 ± 7.1 | 6.4 | 6 |
| Pathology stage, n (%) | ||||||||||||||||||
| ≦pT2 | 52 (86.7%) | 43 (82.7%) | 77 (84.6%) | 118 (86.8%) | 71 (84.6%) | 64 (85.3%) | 90 (62.5%) | 127 (69.4%) | 815 (59.6%) | 585 (58.0%) | 38 (63.3%) | 38 (63.3%) | 77 (77.0%) | 67 (67.0%) | 63 (72.4%) | 49 (67.1%) | ||
| ≥pT3 | 8 (13.3%) | 9 (17.3%) | 14 (15.4%) | 18 (13.2%) | 4 (5.3%) | 11 (14.7%) | 54 (37.5%) | 56 (30.6%) | 562 (40.8%) | 424 (42.0%) | 22 (36.7%) | 22 (36.7%) | 23 (23.0%) | 33 (33.0%) | 24 (27.6%) | 24 (33.9%) | ||
| Overall PSM, n (%) | 6 (10.0%) | 8 (15.4%) | 6 (6.6%) | 21 (15.4%) | 10 (13.3%) | 9 (12.0%) | 22 (15.3%) | 25 (13.7%) | 366 (26.6%) | 316 (31.3%) | 12 (20.0%) | 16 (26.6%) | 14 (14.0%) | 19 (19.0%) | 12 (13.8%) | 9 (12.3%) | ||
| pT2, PSM, n/M(%) | 4/52 (7.7%) | 3/43 (7.0%) | 9/71 (12.7%) | 7/64 (10.9%) | 6/90 (6.7%) | 14/127 (11.0%) | 6/37 (16.2%) | 5/37 (13.5%) | 5/77 (6.5%) | 6/67 (9.0%) | 0/63 (0%) | 0/49 (0%) | ||||||
| >pT3 PSM, n/M(%) | 2/8 (25.0%) | 5/9 (55.6%) | 1/4 (25.0%) | 2/11 (18.2%) | 16/54 (29.6%) | 11/56 (19.6%) | 6/22 (27.3%) | 11/22 (50.0%) | 9/23 (39.1%) | 13/33 (39.4%) | 12/24 (50.0%) | 9/24 (37.5%) | ||||||
| Follow-up, mo | 12 | 12 | 21 | 18 | 48 | 17 | 12 | 12 | 19 | 13 | 39 | 15.4 | 12 | 12 | 3 | 3 | 3 | 3 |
| BCR definition, ng/ml | PSA ≥0.2 | PSA ≥0.2 | PSA ≥0.2 | PSA >0.1 | PSA ≥0.2 | PSA ≥0.2 | PSA ≥0.2 | PSA ≥0.2 | PSA ≥0.4 | |||||||||
| Overall BCR, n/N (%) | 2/60 (3.3%) | 4/52 (7.7%) | 0/91 (0%) | 6/136 (4.4%) | 4.75 (6.7) | 5/75 (5.3) | 10/89 (11.2) | 5/97 (5.3) | 24/144 (16.7) | 24/183 (13.1) | 248/1377 (18.0) | 104/1009 (10.3) | 4/53 (7.5) | 1/50 (2.0) | 6/100 (6.0) | 8/100 (8.0) | 2/87 (2.3) | 1/73 (1.4) |
LRP, laparoscopic radical prostatectomy; RARP, robot-assisted radical prostatectomy; PSM, positive surgical margin; BCR, biochemical recurrence; PSA, prostate-specific antigen; RCT, randomized controlled trial.